# Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

> **NCT00392496** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Stage IV Adult Diffuse Large Cell Lymphoma

## Interventions

- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00392496
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392496, "Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00392496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*